LYEL — Lyell Immunopharma Inc
NASDAQ · Biotechnology · Biotechnology
- Latest Close
- $24.78
- 30-Day Move
- -25.8%
- Market Cap
- $494M
- Shares Outstanding
- 23,310,000
- P/B Ratio
- 2.63
- ROE
- -110.6%
Lyell Immunopharma Inc
A read-only Alphactor snapshot for Lyell Immunopharma Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of 2026-04-22
Topline snapshot
Latest Close
$24.78
30-Day Move
-25.8%
Market Cap
$494M
Shares Outstanding
23,310,000
P/B Ratio
2.63
ROE
-110.6%
$24.78
-25.8%last 90 delayed daily bars
90D High
$45.00
90D Low
$17.34
Avg Volume
107,401
Net margin is -762355.6%, useful for comparing LYEL against peers in Biotechnology.
LYEL is down 25.8% over the last 30 trading days shown on this page.
Latest operating income is $-61M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$0.40
Rule of 40
-418941.0%
Latest Close
$24.78
30-Day Move
-25.8%
Market Cap
$494M
Shares Outstanding
23,310,000
P/B Ratio
2.63
ROE
-110.6%
ROA
-80.7%
Operating Margin
-745394.4%
Net Margin
-762355.6%
Debt / Equity
0
Current Ratio
5.28
Latest Revenue
$6,000
Revenue
$6,000
Gross Profit
--
Operating Income
$-61M
Net Income
$-141M
Gross Margin
--
Net Margin
-76235556.0%
Current Ratio
5.28
Debt / Equity
0.00
Fair Value
$0.40
Upside / Downside
-98.4%
Signal
Overvalued
Implied Growth
--
EV/Rev
$0.40
Growth Assumption
-10.0%
Discount Rate
10.5%
Terminal Growth
2.0%
Base FCF
--
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative FCF — company is cash-flow negative. Reverse DCF requires positive cash flows.
Altman Z
-4.65
Distress
Piotroski
1
Weak (0-3)
Cash Conversion
0.55x
Rule of 40
-418941.0%
Concerning
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $85M | $-187M | $-183M | $-194M |
| 2023-12-31 | $130,000 | $-247M | $-235M | $-166M |
| 2024-12-31 | $61,000 | $-220M | $-343M | $-163M |
| 2025-12-31 | $36,000 | $-202M | $-274M | $-151M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Charles Schwab
Filed 2025-08-12
--
--
Vanguard Group
Filed 2025-08-11
--
--
Northern Trust
Filed 2025-08-13
--
--
Invesco
Filed 2025-11-13
--
--
Geode Capital Management
Filed 2025-08-08
--
--
Two Sigma Advisers
Filed 2025-08-14
--
--
BlackRock
Filed 2024-05-10
$31M
--
Citadel Advisors
Filed 2026-02-17
$10M
--
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.